Association Between Stroke and Adrenal Incidentalomas

Study Purpose

Adrenal incidentalomas (AIs) are commonly encountered in transsection imaging which purpose not for suspected adrenal disease. However, part of AIs in patients is associated with Stroke. Stroke is a diseases which could cause of disability and death worldwide. In clinical practice, detailed information about the association between stroke and AIs is not available. In this study, the investigators aimed to investigate the risk for disability and death in the large group of stroke patients with AIs.

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

No
Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.


Searching Both is inclusive of interventional and observational studies.

Observational [Patient Registry]
Eligible Ages 18 Years and Over
Gender All
More Inclusion & Exclusion Criteria

Inclusion Criteria:

  • - stroke disease , such as Cerebral infarction、Intracerebral hemorrhage and Subarachnoid hemorrhage.

Exclusion Criteria:

  • - presence of metastatic cancer; - AIs smaller than 1 cm; - nonadenoma lesions, such as myelolipomas,hemorrhages, and cysts; - oral glucocorticoid treatment with more than single doses in the past 3 months; - use of inhaled steroids or medication affecting dexamethasone metabolism; - systemic estrogen treatment.

Trial Details

Trial ID:

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.

NCT05237817
Phase

Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

Xuanwu Hospital, Beijing
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

Tong W Ou, Dr.
Principal Investigator Affiliation Department of Urology, Xuanwu Hospital, Capital Medical University
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

Other
Overall Status Recruiting
Countries China
Conditions

The disease, disorder, syndrome, illness, or injury that is being studied.

Stroke, Adrenal Incidentaloma
Additional Details

Background: Adrenal incidentalomas (AIs) are commonly encountered in transsection imaging which purpose not for suspected adrenal disease. However, part of AIs in patients is associated with Stroke . The investigators aimed to investigate the risk for disability and death in the large group of stroke patients with AIs. Objective: To measure the association between stroke and levels of autonomous cortisol secretion in patients with AIs. Design: Part 1, Retrospective cohort study. From April 1, 2021, to September 30, 2021, cohort patients with stroke were recruited in this study. The investigators assess the standardised incidence rate of AIs in all patients. Meanwhile, detail information about stroke disease、patient and AIs characteristics were record. Part 2, Prospective cohort study. From Mar 1, 2022, to Feb 29, 2024, cohort patients with stroke plane to recruit in this study. All patient receive the plasma cortisol level after a 1-mg dexamethasone suppression test. The investigators assess the standardised incidence rate of AIs in all patients. Meanwhile, detail information about stroke disease、patient and AIs characteristics would be record.

Arms & Interventions

Arms

: Cerebral infarction Group

Patients with cerebral infarction, and enrolled in our emergency or clinical department.

: Intracerebral hemorrhage Group

Patients with intracerebral hemorrhage, and enrolled in our emergency or clinical department.

: Subarachnoid hemorrhage Group

Patients with subarachnoid hemorrhage, and enrolled in our emergency or clinical department.

Interventions

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

International Sites

Hao Yan, Beijing, China

Status

Recruiting

Address

Hao Yan

Beijing, , 100053

Site Contact

Hao Yan, Dr.

[email protected]

86-13651341058

Stay Informed & Connected